Report cover image

Vaginitis Therapeutics Market - By Disease Type (Bacterial Vaginosis, Candidiasis), Drug Class (Anti-bacterial, Anti-fungal), Route of Administration (Oral, Topical), Mode (OTC, Prescription), Distribution Channel (Hospital), Global Forecast (2023-2032)

Publisher Global Market Insights
Published Oct 30, 2023
Length 170 Pages
SKU # GMI18367095

Description

Vaginitis Therapeutics Market - By Disease Type (Bacterial Vaginosis, Candidiasis), Drug Class (Anti-bacterial, Anti-fungal), Route of Administration (Oral, Topical), Mode (OTC, Prescription), Distribution Channel (Hospital), Global Forecast (2023-2032)


Global Vaginitis Therapeutics Market will grow at 7.6% CAGR from 2023 to 2032 due to lifestyle changes, escalating healthcare expenditure, and continuous pharmaceutical innovations. Evolving lifestyles contribute to increased incidences of vaginal infections, propelling demand for effective therapeutics. Growing healthcare spending fosters advanced treatment options while ongoing pharmaceutical innovations cater to diverse patient needs. This convergence of factors will position the vaginitis therapeutics market for substantial growth, responding to the dynamic interplay between lifestyle shifts, healthcare investment, and advancements in pharmaceutical solutions.

For instance, in 2023, researchers at Nanjing University developed a nanozyme hydrogel with probiotic properties designed to manage the vaginal microenvironment for the treatment of Candida vaginitis. This breakthrough will strengthen the vaginitis therapeutics market outlook by introducing an effective solution for managing the vaginal microenvironment, addressing a crucial aspect of treatment, and potentially expanding market opportunities.

The vaginitis therapeutics market is segregated based on disease type, route of administration, and region.

The industry size from the candidiasis segment will capture significant gains through 2032, driven by the widespread occurrence of Candida-related infections in the vaginal area. Candidiasis, a common form of vaginitis, prompts a high demand for targeted therapeutics. With a focus on effective and tailored treatments, the market's trajectory is shaped by the substantial share held by candidiasis within the disease type segment, reflecting its prevalent impact on vaginitis cases.

The oral segment will exhibit significant growth and garner a noticeable vaginitis therapeutics market share by 2032. This prominence stems from the convenience and patient preference associated with oral medications. As pharmaceutical advancements continue to improve oral formulations, their effectiveness and ease of use contribute to the growing demand for oral therapeutics in treating vaginitis. With a focus on patient-centric solutions, the oral route will emerge as a pivotal factor shaping the market and holding a major share.

Asia-Pacific vaginitis therapeutics industry will register a notable CAGR from 2023 to 2032, fueled by factors such as increasing awareness of women's health, rising healthcare expenditure, and the growing prevalence of vaginitis in the region. With a burgeoning population and advancing healthcare infrastructure, Asia-Pacific will be a key contributor to the market by 2032. As the demand for effective therapeutics continues to rise, the region's contribution will shape the growth trajectory and maintain a major share in the vaginitis therapeutics industry.

Table of Contents

170 Pages
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Vaginitis therapeutics market 360o synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Disease type trends
2.1.4 Drug class trends
2.1.5 Route of administration trends
2.1.6 Mode trends
2.1.7 Distribution channel trends
Chapter 3 Vaginitis Therapeutics Market Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 High prevalence of vaginal infections
3.2.1.2 Growing awareness about women's health and the availability of effective treatments
3.2.1.3 Advancements in drug developmentIncreasing cases of cancer
3.2.2 Industry pitfalls & challenges
3.2.2.1 Growing antibiotic resistance
3.3 Growth potential analysis
3.3.1 By disease type
3.3.2 By drug class
3.3.3 By route of administration
3.3.4 By mode
3.3.5 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Vaginitis Therapeutics Market Size and Forecast, By Disease Type, 2018 - 2032 (USD Million)
5.1 Key trends, by disease type
5.2 Bacterial vaginosis
5.3 Candidiasis
5.4 Trichomoniasis
5.5 Other disease types
Chapter 6 Vaginitis Therapeutics Market Size and Forecast, By Drug Class, 2018 - 2032 (USD Million)
6.1 Key trends, by drug class
6.2 Anti-bacterial
6.3 Anti-fungal
6.4 Anti-protozoal
6.5 Other drug classes
Chapter 7 Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2018 - 2032 (USD Million)
7.1 Key trends, by route of administration
7.2 Oral
7.3 Topical
Chapter 8 Vaginitis Therapeutics Market Size and Forecast, By Mode, 2018 - 2032 (USD Million)
8.1 Key trends, by mode
8.2 Over-the-counter
8.3 Prescription
Chapter 9 Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2018 - 2032 (USD Million)
9.1 Key trends, by distribution channel
9.2 Hospital pharmacy
9.3 Retail pharmacy
9.4 Online pharmacy
Chapter 10 Vaginitis Therapeutics Market Size and Forecast, By Region (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East & Africa
Chapter 11 Company Profiles
11.1 Pfizer, Inc.
11.2 Merck & Co.
11.3 Novartis AG
11.4 Bayer AG
11.5 Lupin Pharmaceuticals, Inc.
11.6 Sanofi SA
11.7 Dr. Reddy's Laboratories Ltd
11.8 Sun Pharmaceuticals Pvt Ltd
11.9 Cipla Ltd
11.10 Takeda Pharmaceuticals
11.11 Astellas Pharma

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us